Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  House, Stacey L ^a   Branch, Kevin ^a   Newman, Gilbert ^a   Doetschman, Thomas ^a   Schultz, Jo El J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Extracellular signal regulated kinase; Ischemia reperfusion injury; Mitogen activated protein kinase; Myocardial infarction; p38; Signaling cross talk

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; FIBROBLAST GROWTH FACTOR 2; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UO 126;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEAT-SHOCK PROTEINS; MALE; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 27144502042     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00392.2005     Document Type: Article

References (54)

1. Armstrong SC. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 61: 427-436, 2004.
2. Barancik M, Htun P, Strohm C, Kilian S, and Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol 35: 474-483, 2000.
3. Bikfalvi A, Klein S, Pintucci G, and Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 18: 26-45, 1997.
4. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, and Sugden PH. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 79: 162-173, 1996.
5. Bonni A, Brunei A, West AE, Datta SR, Takasu MA, and Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286: 1358-1362, 1999.
6. Clerk A and Sugden PH. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 426: 93-96, 1998.
7. Clerk A and Sugden PH. Untangling the web: specific signaling from PKC isoforms to MAPK cascades. Circ Res 89: 847-849, 2001.
8. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, and Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233, 1995.
9. Debiais F, Lemonnier J, Hay E, Delannoy P, Caverzasio J, and Marie PJ. Fibroblast growth factor-2 (FGF-2) increases N-cadherin expression through protein kinase C and Src-kinase pathways in human calvaria osteoblasts. J Cell Biochem 81: 68-81, 2001.
10. Detillieux KA, Sheikh F, Kardami E, and Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 57: 8-19, 2003.
11. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, and Trzaskos JM. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998.
12. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, and Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101: 593-600, 1981.
13. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, and Saklatvala J. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78: 1039-1049, 1994.
14. Frodin M and Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 151: 65-77, 1999.
15. Fryer RM, Auchampach JA, and Gross GJ. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc Res 55: 520-525, 2002.
16. Fryer RM, Pratt PF, Hsu AK, and Gross GJ. Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection. J Pharmacol Exp Ther 296: 642-649, 2001.
17. Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, and Han J. MAPKK-independent activation of p38a mediated by TAB1-dependent autophosphorylation of p38a. Science 295: 1291-1294, 2002.
18. Ghatan S, Larner S, Kinoshita Y, Hetman M, Patel L, Xia Z, Youle RJ, and Morrison RS. p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol 150: 335-347, 2000.
19. Gorog DA, Tanno M, Cao X, Bellahcene M, Bassi R, Kabir AM, Dighe K, Quinlan RA, and Marber MS. Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia. Cardiovasc Res 61: 123-131, 2004.
20. Gum RJ, McLaughlin MM, Kumar S, Wang Z, Bower MJ, Lee JC, Adams JL, Livi GP, Goldsmith EJ, and Young PR. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem 273: 15605-15610, 1998.
21. Hampton TG, Amende I, Fong J, Laubach VE, Li J, Metais C, and Simons M. Basic FGF reduces stunning via a NOS2-dependent pathway in coronary-perfused mouse hearts. Am J Physiol Heart Circ Physiol 279: H260-H268, 2000.
22. 2 synthesis in endo-thelium. Am J Physiol Cell Physiol 281: C1266-C1276, 2001.
23. House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G, and Schultz JJ. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 108: 3140-3148, 2003.
24. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J, Cattini PA, Dixon IM, and Kardami E. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 282: H1071-H1080, 2002.
25. Khurana R, Martin JF, and Zachary I. Gene therapy for cardiovascular disease: a case for cautious optimism. Hypertension 38: 1210-1216, 2001.
26. Knight RJ and Buxton DB. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun 218: 83-88, 1996.
27. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, and Vlahos CJ. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK α is the predominant isoform expressed in human heart. J Mol Cell Cardiol 33: 1527-1540, 2001.
28. Liao P, Wang SQ, Wang S, Zheng M, Zhang SJ, Cheng H, Wang Y, and Xiao RP. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res 90: 190-196, 2002.
29. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, and Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell 72: 269-278, 1993.
30. Liu Q and Hofmann PA. Protein phosphatase 2A-mediated cross talk between p38 MAPK and ERK in apoptosis of cardiac myocytes. Am J Physiol Heart Circ Physiol 286: H2204-H2212, 2004.
31. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, Wang C, Lee JC, Feuerstein GZ, and Yue TL. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99: 1685-1691, 1999.
32. Mackay K and Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem 274: 6272-6279, 1999.
33. Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, and Das DK. Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2. Am J Physiol Heart Circ Physiol 275: H1857-H1864, 1998.
34. Murry CE, Jennings RB, and Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
35. Nakano A, Cohen MV, Critz S, and Downey JM. SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol 95: 466-471, 2000.
36. Ornitz DM and Itoh N. Fibroblast growth factors. Genome Biol 2: 3005.1-3005.12, 2001.
37. Powers CJ, McLeskey SW, and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197, 2000.
38. Ravingerova T, Barancik M, and Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247: 127-138, 2003.
39. Saurin AT, Martin JL, Heads RJ, Foley C, Mockridge JW, Wright MJ, Wang Y, and Marber MS. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J 14: 2237-2246, 2000.
40. Schneider S, Chen W, Hou J, Steenbergen C, and Murphy E. Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol Heart Circ Physiol 280: H499-H508, 2001.
41. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 97: 276-285, 2002.
42. Strohm C, Barancik T, Bruhl ML, Kilian SA, and Schaper W. Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol 36: 218-229, 2000.
43. Sumida T, Otani H, Kyoi S, Okada T, Fujiwara H, Nakao Y, Kido M, and Imamura H. Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580. Am J Physiol Heart Circ Physiol 288: H2726-H2734, 2005.
44. Talmor D, Applebaum A, Rudich A, Shapira Y, and Tirosh A. Activation of mitogen-activated protein kinases in human heart during cardiopulmonary bypass. Circ Res 86: 1004-1007, 2000.
45. RSK blocks Bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem 274: 34859-34867, 1999.
46. Tanaka K, Abe M, and Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res 90: 647-654, 1999.
47. Tanno M, Gorog DA, Bellahcene M, Cao X, Quinlan RA, and Marber MS. Tumor necrosis factor-induced protection of the murine heart is independent of p38-MAPK activation. J Mol Cell Cardiol 35: 1523-1527, 2003.
48. Torocsik B and Szeberenyi J. Anisomycin uses multiple mechanisms to stimulate mitogen-activated protein kinases and gene expression and to inhibit neuronal differentiation in PC12 phaeochromocytoma cells. Eur J Neurosci 12: 527-532, 2000.
49. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, and Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273: 2161-2168, 1998.
50. Weinbrenner C, Liu GS, Cohen MV, and Downey JM. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol 29: 2383-2391, 1997.
51. Xiao YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, Bratton DL, and Henson PM. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-β. J Biol Chem 277: 14884-14893, 2002.
52. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, and Ohlstein EH. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86: 692-699, 2000.
53. Zhang H, Shi X, Hampong M, Blanis L, and Pelech S. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem 276: 6905-6908, 2001.
54. Zhuang S, Demirs JT, and Kochevar IE. p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. J Biol Chem 275: 25939-25948, 2000.